Skip to content
Dx

ICD-10-CM 2027 diagnosis code

Z19.2Hormone resistant malignancy status

✓ Billable / specificPOA exemptNot a principal dx

Z19.2 is a valid, billable ICD-10-CM code for hormone resistant malignancy status. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.

Code last changed in FY2017 (effective October 1, 2016). Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data

About Z19.2

Z19.2 is the ICD-10-CM diagnosis code for hormone resistant malignancy status. It belongs to category Z19 (hormone sensitivity malignancy status), block Z19 (hormone sensitivity malignancy status) and chapter 21 (factors influencing health status and contact with health services). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within Z19 (hormone sensitivity malignancy status), Z19.2 is specifically for hormone resistant malignancy status. Related codes cover sensitive malignancy status (Z19.1).

Code first: malignant neoplasm - see Table of Neoplasms, by site, malignant.

It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.

In MS-DRG v44.0, it is part of the grouping logic for DRG 951 (Other Factors Influencing Health Status, relative weight 0.5577), in MDC 23 (Factors Influencing Health Status and Other Contacts with Health Services), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It is not acceptable as the principal diagnosis for an inpatient stay; it may be reported as a secondary diagnosis.

It is exempt from present-on-admission (POA) reporting, so no POA indicator is required.

It was added in FY2017, effective October 1, 2016.

Coding notes

Applicable toConditions and synonyms classified to this code
  • Castrate resistant prostate malignancy status

Notes that apply from higher levels

Instructions written at a parent level also apply to Z19.2.

› From Z19 Hormone sensitivity malignancy status
Code first
  • malignant neoplasm - see Table of Neoplasms, by site, malignant

Broader instructions also apply from Chapter 21: Factors influencing health status and contact with health services.

Alphabetic index entries

2 entries

Terms in the official ICD-10-CM index that lead to Z19.2.

Codes whose notes reference Z19.2

  • C61Use additional code

MS-DRG v44.0 grouping

All DRGs →

Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.

MDC 23 · Factors Influencing Health Status and Other Contacts with Health Services

Code history

  1. 2016
  2. 2017
  3. 2018
  4. 2019
  5. 2020
  6. 2021
  7. 2022
  8. 2023
  9. 2024
  10. 2025
  11. 2026
  12. 2027
  • FY2017 (effective 10/1/2016): Added
  • No changes since FY2017.

Common questions about Z19.2

Is Z19.2 billable?

Yes. Z19.2 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).

Can Z19.2 be used as a principal diagnosis?

No. It is not acceptable as the principal diagnosis for an inpatient stay; it may be reported as a secondary diagnosis.

Is Z19.2 a CC or MCC?

No. Z19.2 is neither a CC nor an MCC under MS-DRG v44.0.

What DRG does Z19.2 group to?

Z19.2 is used in the MS-DRG v44.0 logic for MS-DRG 951 (Other Factors Influencing Health Status). Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.